SMi Group reports: Leading organizations in the Biosimilars Development sector will meet at Biosimilars and Biobetters USA 2015 – the must-attend premier industry event which will take place in Iselin this November.
Iselin, NJ, August 07, 2015 –(PR.com)– In recent weeks, the industry has been thriving with news about Biosimilars and Biobetters with a court allowing Sandoz to launch the first US biosimilar in September, Oncobiologics to raise $31M for a Phase III biosimilar play against Humira, and Merck and Samsung’s Humira biosimilar to come through in Phase III.
With all of this happening, SMi Group is excited to announce that John Pakulski, Head US Biopharmaceutical Regulatory Affairs, Sandoz, will be giving a spotlight presentation on “The First Biosimilar Approved by the FDA.” Oncobiologics will be the co-host of the post-conference workshop on “Development, Regulatory & Commercial Needs for Global Biosimilars,” while Merck and Samsung Bioepis confirming their attendance.
The Biosimilars and Biobetters USA 2015, taking place in Iselin, USA, on the 16th and 17th of November, will enable attendees to understand the latest B&B markets, from rebranding to regulatory landscape. Over 80 industry experts from the world’s leading pharmaceutical and biotech companies will meet in New Jersey to discuss the current challenges and solutions to accelerate commericialization. Through practical case studies and workshops, attendees will gain a 360⁰ overview of the global B&B market to ensure ROI for investments. For more information on the event visit www.biosimilars-usa.com/prcom
Through attending Biosimilars & Biobetters USA 2015, you will:
• Hear the latest on the evolving regulatory biosimilar landscape and review the guidelines
• Gain understanding of strategies for market access and commercialization of products
• Learn about global biosimilar market developments, in particular the lucrative opportunities in emerging markets
In addition to the conference, the event will feature two post-conference workshops:
• “A Regulatory Perspective on Biosimilars” (led by Ravi S. Harapanhalli, Vice President, ParExel and former Senior Executive, FDA) and
• “Development, Regulatory & Commercial Needs for Global Biosimilars” (led by Gerry McGettigan, CEO & Regulatory Expert and Graeme Deuchar, Product Development Expert from Kinesys Consulting Ltd, and Liz Yamashita, VP, Regulatory & Clinical Affairs, Oncobiologics.)
Expert speakers 2015 also include senior representatives from ParExel, Merck, Formycon AG, Dr. Reddy’s Laboratories, Inc, AGES Regulatory Agency, Janssen Research and Development, LLC, IMS Health, Norwegian Medicines Agency and many more. For more information on the speakers 2015 visit www.biosimilars-usa.com/prcom
Biosimilars & Biobetters USA 2015 is proudly sponsored by Schwegman Lundberg & Woessner
Early bird places are strictly limited. To take advantage of this, please register today at www.biosimilars-usa.com/prcom
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk